Gain-of-function mutations of FLT3 by internal tandem duplication (ITD) in the juxtamembrane domain or point mutations in its tyrosine kinase domains (FLT3-TKD) were found in approximately 30 to 40% of AML patients, engendering poor prognostic outcomes [4,6]. The gene discussed is FLT3; the disease is acute myeloid leukemia.